Progyny (NASDAQ:PGNY) Updates Q1 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its first quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.420-0.450 for the period, compared to the consensus EPS estimate of 0.390. The company issued revenue guidance of $319.0 million-$332.0 million, compared to the consensus revenue estimate of $344.9 million. Progyny also updated its FY 2026 guidance to 1.830-1.950 EPS.

Progyny Stock Up 4.3%

Shares of Progyny stock traded up $0.92 during trading hours on Thursday, hitting $22.25. 1,852,843 shares of the company’s stock traded hands, compared to its average volume of 1,439,322. Progyny has a twelve month low of $17.98 and a twelve month high of $28.75. The company has a market cap of $1.92 billion, a PE ratio of 35.32, a PEG ratio of 1.31 and a beta of 0.96. The stock has a 50 day simple moving average of $24.16 and a 200-day simple moving average of $23.14.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.24). Progyny had a net margin of 4.46% and a return on equity of 10.71%. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, equities research analysts predict that Progyny will post 0.6 EPS for the current year.

Wall Street Analysts Forecast Growth

PGNY has been the subject of a number of research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a research note on Monday, December 29th. Barclays began coverage on shares of Progyny in a report on Monday, December 8th. They set an “overweight” rating and a $29.00 price objective for the company. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Canaccord Genuity Group increased their price target on shares of Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. Finally, BTIG Research reiterated a “buy” rating on shares of Progyny in a research note on Wednesday, January 21st. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.80.

Key Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Q4 revenue beat and growth — Progyny reported Q4 revenue of $318.4 million, a 6.7% increase for the quarter and part of the company’s tenth consecutive year of revenue growth. Q4 results press release
• Positive Sentiment: FY‑2026 EPS guidance raised — Management set FY‑2026 EPS guidance at $1.83–$1.95, well above street consensus (~$1.55), suggesting improved profitability expectations. Guidance details
• Positive Sentiment: Strong cash generation and buybacks — Progyny reported record full‑year operating cash flow ($210.2M) and has repurchased ~6.5 million shares under its recent authorization, which supports EPS and shareholder value. Cash flow & buybacks
• Neutral Sentiment: Q1 EPS guidance above consensus but revenue guide below — Progyny gave Q1‑2026 EPS guidance of $0.420–$0.450 (above the $0.39 consensus) while issuing revenue guidance (~$319M–$332M) below the ~$344.9M street estimate, a mixed near-term outlook that tempers the FY optimism. Q1 guidance article
• Neutral Sentiment: Analyst commentary and valuation checks — Coverage pieces and previews are assessing retention strength, growth initiatives and whether recent share-price weakness presents a valuation opportunity; these conversations may influence positioning but are not immediate catalysts. Analyst preview
• Negative Sentiment: Q4 EPS miss — Progyny reported GAAP EPS of $0.14 for Q4, missing the ~$0.38 consensus by $0.24, which explains part of the stock’s intra‑day mixed reaction despite the revenue beat. Earnings snapshot
• Negative Sentiment: Rising short interest — Short interest jumped ~41% in February to >4.0M shares (≈5.1% of float), increasing downside pressure and the potential for sharper moves on negative headlines. (Short-interest data reported Feb 25.)

Institutional Trading of Progyny

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. boosted its position in Progyny by 17.2% during the 4th quarter. Invesco Ltd. now owns 466,769 shares of the company’s stock valued at $11,987,000 after purchasing an additional 68,473 shares during the period. Caitlin John LLC increased its position in Progyny by 72.3% in the fourth quarter. Caitlin John LLC now owns 12,796 shares of the company’s stock worth $329,000 after buying an additional 5,371 shares during the period. EP Wealth Advisors LLC acquired a new stake in Progyny in the fourth quarter worth $275,000. XTX Topco Ltd bought a new stake in Progyny in the fourth quarter valued at $3,058,000. Finally, VARCOV Co. acquired a new position in shares of Progyny during the fourth quarter valued at $491,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.